Orgenesis Ranked 5th Fastest Growing Technology Company in Maryland and 208th in North America on Deloitte's 2019 Technology Fast 500
Germantown MD, US, November 29, 2019 - Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary Masthercell Global, Inc., as well as localized point-of-care development and processing centers, today announced it has been ranked the 5th fastest growing technology company in Maryland and 208th in North America on Deloitte’s 2019 Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Orgenesis’ revenue increased 527 percent during the period from 2015 to 2018.
Vered Caplan, CEO of Orgenesis, commented, “We are very proud to receive this recognition from Deloitte on their prestigious 2019 Technology Fast 500 list. We continue to establish ourselves as an industry leader in the cell and gene therapy space through our Contract Development and Manufacturing Organization (“CDMO”) business, as well as our rapidly evolving POCare platform. We are rapidly gaining traction in the market, as evidenced by our strong year-over-year growth, and remain focused on our goal of bringing autologous therapies to patients in a cost effective, high quality and scalable manner.”
About Deloitte’s 2019 Technology Fast 500(TM)
Now in its 25th year, Deloitte’s Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2015 to 2018.
Orgenesis is a biopharmaceutical company specializing in the development, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates through two platforms: (i) a point-of-care (“POCare”) cell therapy platform (“PT”) and (ii) a Contract Development and Manufacturing Organization (“CDMO”) platform conducted through its subsidiary, Masthercell Global. Through its PT business, the Company’s aim is to further the development of Advanced Therapy Medicinal Products (“ATMPs”) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patients. The Company out-licenses these ATMPs through regional partners to whom it also provides regulatory, pre-clinical and training services to support their activity in order to reach patients in a point-of-care hospital setting. Through the Company’s CDMO platform, it is focused on providing contract manufacturing and development services for biopharmaceutical companies. Additional information is available at: www.orgenesis.com.